CAS 943540-74-7

Formule : C20H12F2N6

InChI : InChI=1S/C20H12F2N6/c21-20(22,15-3-4-16-14(12-15)2-1-9-24-16)19-26-25-18-6-5-17(27-28(18)19)13-7-10-23-11-8-13/h1-12H

Code InChI : KOAWAWHSMVKCON-UHFFFAOYSA-N

SMILES : C1=CC2=C(C=CC(=C2)C(C3=NN=C4N3N=C(C=C4)C5=CC=NC=C5)(F)F)N=C1

JNJ-38877618

CAS : 943540-74-7

JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively).

Formule : C₂₀H₁₂F₂N₆

Degré de pureté : 98.84% - 99.74%

Couleur et forme : Yellow Solid

Masse moléculaire : 374.3463

Ref: TM-T15617

JNJ-38877618

CAS : 943540-74-7

JNJ-38877618

Formule : C₂₀H₁₂F₂N₆

Degré de pureté : ≥98%

Masse moléculaire : 374.35

Ref: 54-BUP08597

JNJ-38877618

CAS : 943540-74-7

6-(Difluoro(6-(pyridin-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl)quinoline

Formule : C₂₀H₁₂F₂N₆

Degré de pureté : 99%

Masse moléculaire : 374.35

Ref: IN-DG00794771

JNJ-38877618(OMO-1)

CAS : 943540-74-7

JNJ-38877618(OMO-1) is a novel synthetase inhibitor that has been shown to have potent anti-tumor activity in vitro and in vivo. This drug selectively inhibits the synthesis of siderophores by the iron transporter, ferric reductase, and is also effective against neutrophil chemotaxis. JNJ-38877618(OMO-1) has a low bioavailability and poor solubility, which limits its use as an oral drug. However, it has been shown to be safe when used at high doses in mice. The safety profile of this drug is yet to be determined during clinical development.

Formule : C₂₀H₁₂F₂N₆

Degré de pureté : Min. 95%

Masse moléculaire : 374.35 g/mol

Ref: 3D-TMB54074